Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022
Source: The Oncologist - Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research